BioSpace News Archive

Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2023 financial results before the market opens on Monday, August 14, 2023.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that presentations will be delivered at the American Society of Retina Specialists 41st Annual Scientific Meeting and the Ophthalmology Innovation Source Retina Innovation Summit taking place July 27 – August 1, 2023 in Seattle, WA.

Triastek, Inc. (“Triastek”), a global healthcare company developing medicines with proprietary, pioneering 3D printing processes, today announced they have completed its first human (FIH) study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC).

MediView XR, Inc., a leading clinical augmented reality med-tech company, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its XR90 augmented reality-based surgical visualization and navigation platform.

BioSig Technologies, Inc. today announced that its subsidiary BioSig AI Sciences, Inc. (BAIS) was selected to join NVIDIA Inception, a program designed to partner with companies revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023.

BBI-001 was well tolerated with no dose limiting toxicities. Single-dose administration demonstrated a statistically significant reduction of dietary iron absorption.

argenx announced that it will host a conference call and audio webcast on Thursday, July 27, 2023 at 2:30 pm CET to discuss its half year 2023 financial results and provide a second quarter business update.

Genentech, a member of the Roche Group, announced that data from its ophthalmology portfolio will be highlighted in 25 abstracts at the 2023 American Society of Retina Specialists Annual Meeting, which will be held from July 28 to August 1 in Seattle, WA.

Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.